Asieris Pharmaceuticals licenses CEVIRA cervical treatment to Theramex for Europe and other markets

Asieris Pharmaceuticals and Theramex have entered into an exclusive licensing agreement for CEVIRA (APL-1702), a non-surgical treatment for cervical precancerous lesions. Valued in excess of 250 million US dollars, the deal grants Theramex exclusive rights in Europe, Australia, New Zealand, and Turkey. The agreement includes a 15 million US dollar upfront payment subject to specific conditions, 11 million US dollars in near-term regulatory milestones, commercial milestones, and tiered royalties.

Asieris-Theramex licensing agreement

• ▪Asieris Pharmaceuticals and Theramex entered into an exclusive licensing agreement for CEVIRA (APL-1702), announced on October 7, 2026.
• ▪Theramex, headquartered in London, is a global specialty pharmaceutical company dedicated to women's health that operates in more than 50 countries.
• ▪The total value of the licensing agreement between Asieris Pharmaceuticals and Theramex for CEVIRA (APL-1702) is in excess of 250 million US dollars.
• ▪Asieris Pharmaceuticals, founded in March 2010, is a global biopharma company specializing in therapies for genitourinary tumors and women's health.

CEVIRA cervical treatment technology

• ▪In March 2026, Asieris Pharmaceuticals announced that CEVIRA had received approval from China's National Medical Products Administration as a first-in-class non-invasive therapy.
• ▪CEVIRA (APL-1702) combines local drug delivery with controlled light activation in an integrated intravaginal device administered by a healthcare professional and removed at home by the patient.
• ▪CEVIRA (APL-1702) is a photodynamic drug-device combination product being developed as a non-surgical treatment for cervical precancerous lesions associated with HPV.

Deal upfront payment structure

• ▪The licensing agreement includes a total of 11 million US dollars in near-term regulatory milestone payments, alongside commercial milestone payments and tiered royalties.
• ▪The licensing agreement includes a 15 million US dollar upfront payment to Asieris Pharmaceuticals, which is subject to specific conditions.
• ▪The upfront payment conditions include signing a supply agreement, successful manufacturing site audits, streamlining with the upstream licensing agreement, and European Commission clarification on clinical value assessment.

European territory rights

• ▪The agreement is expected to grant Theramex exclusive rights to CEVIRA in Europe, Australia, New Zealand, and Turkey.
• ▪Asieris Pharmaceuticals retains the rights to CEVIRA for the rest of the world outside of Europe, Australia, New Zealand, and Turkey.

Debatable claims

• ▪Non-surgical treatments for cervical precancerous lesions are safer than surgical options
• ▪The European Commission's clinical value assessments for drug-device combinations are too restrictive